{"id":685,"date":"2010-08-26T15:22:36","date_gmt":"2010-08-26T19:22:36","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=685"},"modified":"2010-08-26T15:22:36","modified_gmt":"2010-08-26T19:22:36","slug":"foundation-funds-rd-for-alzheimers-precursor-treatment","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=685","title":{"rendered":"Foundation Funds R&#038;D for Alzheimer&#8217;s Precursor Treatment"},"content":{"rendered":"<p>The <a href=\"http:\/\/www.alzdiscovery.org\/\">Alzheimer&#8217;s Drug Discovery Foundation<\/a> (ADDF) has awarded a grant of $240,000 to <a href=\"http:\/\/www.agenebio.com\/index.html\">AgeneBio Inc.<\/a> of Indianapolis, Indiana to develop a new class of small molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer&#8217;s disease.<\/p>\n<p>About 15 percent of aMCI patients progress to Alzheimer&#8217;s disease. ADDF says that new research on aMCI shows that excess neural activity is associated with greater memory loss and predicts progression to Alzheimer&#8217;s disease. AgeneBio is developing therapies that are designed to selectively normalize this excess neural activity, improve memory, and slow the progression to Alzheimer&#8217;s disease.<\/p>\n<p>AgeneBio&#8217;s research platform is based on the work of <a href=\"http:\/\/pbs.jhu.edu\/research\/gallagher\/facultyinfo\/\">Michela Gallagher<\/a>, founder of AgeneBio. Gallagher is Professor of Psychology and Neuroscience, and head of the Neurogentics and Behavior Center at Johns Hopkins University in Baltimore, Maryland.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Alzheimer&#8217;s Drug Discovery Foundation (ADDF) has awarded a grant of $240,000 to AgeneBio Inc. of Indianapolis, Indiana to develop a new class of small molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer&#8217;s disease. About 15 percent of aMCI patients progress to Alzheimer&#8217;s disease. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,38],"class_list":["post-685","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-grant"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=685"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/685\/revisions"}],"predecessor-version":[{"id":689,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/685\/revisions\/689"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}